PT-141 (Bremelanotide) and the Melanocortin System: The State of Research

Abstract laboratory-style illustration: five receptor nodes connected to a central ligand, evoking the MC1R to MC5R melanocortin system targeted by PT-141.

PT-141 at a Glance: What the Literature Shows

PT-141, whose international nonproprietary name is bremelanotide, is a peptide analog of the hormone α-MSH (alpha-melanocyte-stimulating hormone). It acts as an agonist of the melanocortin receptors, chiefly MC4R and MC3R, located in the central nervous system. It is this central action — not a direct vascular action like that of PDE5 inhibitors — that distinguishes its mechanism in the scientific literature.

Bremelanotide is the only melanocortin agonist of this kind to have been approved by the US Food and Drug Administration (FDA): on June 21, 2019, under the trade name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval rested on two randomized phase 3 trials, RECONNECT (studies 301 and 302). A key regulatory point: the medicine Vyleesi and the PT-141 sold as a research peptide are two distinct realities. This article reports the state of the literature for scientific information purposes; PT-141 remains a compound strictly reserved for in vitro research.

Origin: From α-MSH to Melanotan II, Then to PT-141

The story of PT-141 begins with α-MSH, a fragment produced by the cleavage of pro-opiomelanocortin (POMC) and involved, among other things, in skin pigmentation. In the 1980s and 1990s, researchers at the University of Arizona synthesized more stable analogs of α-MSH to explore tanning without ultraviolet exposure. One of them, Melanotan II (MT-II), a cyclic heptapeptide, did indeed induce pigmentation in the early tests.

It was during this work that an unexpected effect was observed: several male volunteers reported stimulation of sexual arousal and spontaneous erections, which were not anticipated for a tanning agent. This serendipitous discovery redirected research toward the potential of melanocortins in sexual function. Bremelanotide (PT-141) was developed as a derivative of Melanotan II: chemically, it is a metabolite of that compound, a cyclic heptapeptide lactam analog of α-MSH. Its clinical development was subsequently carried by the company Palatin Technologies.

The Melanocortin System: Five Receptors, Five Functions

The melanocortin system is built on five G-protein-coupled receptors, numbered MC1R to MC5R, and on endogenous ligands derived from POMC: the hormones α-MSH, β-MSH, γ-MSH and ACTH. Two modulators, AgRP (agouti-related peptide) and ASIP, act as antagonists or inverse agonists at some of these receptors. Each receptor has its own tissue distribution and physiological role.

MC1R, expressed in the melanocytes of the skin and hair follicles, regulates pigment synthesis (eumelanin versus phaeomelanin) and thus pigmentation. MC2R, in the adrenal cortex, is highly selective for ACTH and essential for adrenal steroidogenesis and therefore the stress response. MC3R and MC4R, mainly hypothalamic, modulate the central control of food intake and satiety; MC4R is also involved in thermogenesis and energy expenditure.

MC5R, present in exocrine glands (sebaceous glands) as well as in adipocytes and skeletal muscle, participates in sebogenesis and may play a role in lipid metabolism and immunity. This diversity explains why a single biological system links functions as varied as pigmentation, appetite, sexual function and inflammation — and why selectively targeting one of these receptors is a major axis of pharmacological research.

PT-141's Central Mechanism: MC4R and MC3R Agonist

Bremelanotide binds and activates the MC3R and MC4R receptors of the central nervous system. The official labeling of Vyleesi describes it as "a melanocortin receptor agonist" whose "exact mechanism of action is unknown"; it is believed to be linked to the activation of brain melanocortin receptors "thought to be associated with sexual function." This cautious wording reflects the actual state of knowledge: the link between MC4R activation and the modulation of desire is not fully elucidated at the neurobiological level.

The key point for understanding PT-141 is the contrast between its central action and a peripheral vascular action. PDE5 inhibitors, for example, act downstream on vasodilation. Melanocortin agonists, by contrast, are studied for an action upstream, at the level of hypothalamic neural circuits. This mechanistic distinction is repeatedly highlighted in the literature as the hallmark of the melanocortin system in the field of sexual function.

Clinical Path: From the Intranasal Route to HSDD

The clinical development of bremelanotide first explored an intranasal formulation, notably in the context of male erectile dysfunction. This initial program ran into difficulties linked to transient increases in blood pressure observed in the studies, which led Palatin Technologies to reorient the development.

The compound was then reformulated as an as-needed subcutaneous injection and evaluated in premenopausal women with hypoactive sexual desire disorder. This refocusing on female HSDD, with a controlled route of administration and dose, led to the phase 3 program that served as the basis for regulatory approval. This path illustrates a common principle in pharmacology: a single molecule can change indication, route and dose over the course of its development, and data obtained for one formulation cannot be mechanically transposed to another.

The RECONNECT Trials and the 2019 FDA Approval

The two pivotal phase 3 trials, published by Kingsberg and colleagues in Obstetrics & Gynecology in 2019, are known as RECONNECT (study 301, NCT02333071; study 302, NCT02338960). In total, 1,267 premenopausal women with HSDD were randomized, of whom 1,247 were in the safety population and 1,202 in the modified intent-to-treat efficacy population. The dose evaluated was 1.75 mg of bremelanotide by as-needed subcutaneous injection.

The primary endpoints were the "desire" domain of the Female Sexual Function Index (FSFI) and item 13 of the Female Sexual Distress Scale. Women on bremelanotide showed statistically significant increases in sexual desire (study 301: 0.30; study 302: 0.42; integrated analysis: 0.35; P<0.001) and significant reductions in distress related to low desire (study 301: -0.37, P<0.001; study 302: -0.29, P=0.005). The most common adverse events were nausea, flushing and headache, reported in at least 10% of participants in both studies.

On this basis, the FDA approved Vyleesi on June 21, 2019 for acquired, generalized HSDD in premenopausal women. The product is presented as a prefilled autoinjector pen, to be administered about 45 minutes before anticipated sexual activity. Prespecified and integrated subgroup analyses of the RECONNECT trials were later published (2022) to clarify the consistency of results across participant characteristics.

After Approval: Vyleesi's Commercial Path

The medicine's commercial path illustrates the complexity that follows an approval. Vyleesi had initially been licensed to AMAG Pharmaceuticals for North America. In 2020, AMAG and Palatin mutually terminated that license agreement, and the rights reverted to Palatin Technologies.

In December 2023, Palatin announced the divestment of Vyleesi to Cosette Pharmaceuticals. According to Palatin's press release, the transaction provided for an upfront payment of $12 million and sales-based milestone payments that could bring the total value up to $171 million; Cosette took over commercialization of the product in the United States, with transitional services provided by Palatin to maintain patient access. These changes of ownership do not affect the drug's approval status, but they are a reminder that the actual availability of an approved product also depends on industrial and commercial decisions, distinct from the scientific evaluation.

Other Melanocortin Axes: Obesity and Inflammation

Bremelanotide is not the only melanocortin agonist to have reached the regulatory stage. Setmelanotide (Imcivree, developed by Rhythm Pharmaceuticals) selectively targets the MC4R receptor, the central pathway of appetite regulation. It was first approved by the FDA in 2020 for chronic weight management in rare forms of genetic obesity linked to POMC, PCSK1 or LEPR (leptin receptor) deficiency, then extended to other populations, including Bardet-Biedl syndrome and, more recently, acquired hypothalamic obesity.

This example concretely illustrates the physiological role of MC4R described above: its stimulation modulates satiety, and its loss of function is an established monogenic cause of obesity. Beyond appetite and sexual function, the literature explores other axes of the system, notably the anti-inflammatory role of melanocortins — α-MSH and its analogs have immunomodulatory properties studied in various models. Genetic work has also associated polymorphisms of the melanocortin receptors with certain inflammatory traits. These axes remain, for the most part, at the preclinical or exploratory research stage.

Bremelanotide the Medicine vs PT-141 for Research: The Regulatory Point

This is the most important point of the dossier. Bremelanotide as a medicine refers exclusively to Vyleesi: a pharmaceutical product manufactured under good manufacturing practices, dosed, controlled, accompanied by a package insert, approved by the FDA for a precise indication (premenopausal female HSDD) and a defined route of administration. All the efficacy and tolerability data cited in this article were obtained with that pharmaceutical material, within a supervised clinical framework.

PT-141 sold as a research peptide falls into an entirely different category. It is a "Research Use Only" (RUO) product, intended for in vitro research and laboratory work by professionals. It is neither a medicine, nor a supplement, nor a product intended for human or veterinary administration. Nothing allows the results of trials conducted with Vyleesi to be extrapolated to an RUO peptide: purity, dosage, formulation and quality control do not fall under the same regulatory framework. Confusing the two would be a factual and regulatory error.

Limits of the Data and Research Framing

Several limits frame the available literature. The precise central mechanism linking MC4R activation to the modulation of desire is not fully elucidated, as the product's official labeling acknowledges. The RECONNECT trials concerned a specific population — premenopausal women with acquired, generalized HSDD — and their results do not transpose to other populations. The effect sizes on desire scores, while statistically significant, must be interpreted in light of the scales used.

More broadly, the melanocortin system illustrates both the power and the difficulty of selective targeting: a single network links pigmentation, appetite, sexual function and inflammation, which makes pharmacological specificity complex and explains the diversity of reported adverse events (nausea, flushing, blood-pressure changes). This article does not constitute medical advice in any way, and recommends no use, no dose and no consumption. The peptides offered on this site are strictly reserved for research; anyone concerned by a disorder of desire or appetite should consult a healthcare professional.

Sources

Keep reading

EncyclopediaPT-141